Sarepta Therapeutics (SRPT) Return on Capital Employed (2011 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Return on Capital Employed of 1.48% for Q1 2026, up 229.0% year-over-year from 0.45% in Q1 2025, and up 95.08% quarter-over-quarter from 30.08% in Q4 2025.
Sarepta Therapeutics (SRPT) Return on Capital Employed (2011 - 2026) Analysis & Trends
Sarepta Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 1.48% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 229.0% year-over-year to 1.48%; the TTM figure through Mar 2026 stood at 1.48% (up 229.0% YoY), while the FY2025 annual figure was 27.32%, down 3489.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 1.48%, up from 30.08% in the prior quarter.
- The five-year high for Return on Capital Employed was 7.15% in Q4 2024, with the low at 30.08% in Q4 2025.
- The 5-year median for Return on Capital Employed is 10.57% (2023), against an average of 10.35%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 2109 bps in 2024, then plunged 3723 bps in 2025.
- Sarepta Therapeutics' Return on Capital Employed stood at 21.26% in 2022, then soared by 50 bps to 10.57% in 2023, then jumped by 168 bps to 7.15% in 2024, then sank by 521 bps to 30.08% in 2025, then soared by 95 bps to 1.48% in 2026.
- Business Quant data shows SRPT's Return on Capital Employed at 1.48% in Q1 2026, 30.08% in Q4 2025, and 4.75% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | -5.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.34% |
| Mar 31, 2026 | -1.48% |
| Dec 31, 2025 | -30.08% |
| Sep 30, 2025 | -4.75% |
| Jun 30, 2025 | -0.04% |
| Mar 31, 2025 | -3.77% |
| Dec 31, 2024 | 7.15% |
| Sep 30, 2024 | 2.88% |
| Jun 30, 2024 | 1.44% |
| Mar 31, 2024 | -3.60% |
| Dec 31, 2023 | -10.57% |
| Sep 30, 2023 | -14.97% |
| Jun 30, 2023 | -19.65% |
| Mar 31, 2023 | -22.97% |
| Dec 31, 2022 | -21.26% |
| Sep 30, 2022 | -21.64% |
| Jun 30, 2022 | -17.67% |
| Mar 31, 2022 | -14.91% |
| Dec 31, 2021 | -18.75% |
| Sep 30, 2021 | -22.45% |